Video

Dr. Campbell on promise of infigratinib in FGFR3 mutation–positive UTUC

“Several of these patients were able to undergo surgery that spared them the need to remove their ureter and their kidney,” says Matthew T. Campbell, MD.

Matthew T. Campbell, MD, discusses the abstract, “Interim Results From a Phase 1b Clinical Trial Evaluating Tolerability and Activity of FGFR Inhibition in Localized Upper Tract Urothelial Carcinoma (UTUC),” which he presented at the 2022 AUA Annual Meeting (abstract LBA01-10). The interim study data showed that infigratinib demonstrated strongactivity in patients with localized UTUC harboring FGFR3 mutations. Campbell is an assistant professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

Related Videos
Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
Urinary bladder | Image Credit: © magicmine - stock.adobe.com
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
Betty Wang, MD, discusses studies from the 2025 EAU meeting
Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.